Latest News
Why does the impact of an Alzheimer’s risk factor vary by race and genetic ancestry? Researchers are learning the answers.
BrightFocus-funded researchers were among the first to “map” the normal 3D structure of a protein called myocilin, which is abundant in the drainage pathway of the eye. Now, with a second grant, they’ve designed antibodies to help diagnose and treat myocilin misfolding as it contributes to glaucoma.
BrightFocus Honors the Life of John Q. Trojanowski, MD, PhD
Proposed Federal Rule Would Create Chilling Effect on Future Research
In this issue:
- President's Corner
- Researcher Spotlight: Christelle Anaclet, PhD
- Early Success for Proposed New Method of Clearing Toxic Tau
- Is it Alzheimer's? What's Normal, What's Not
- And more!
The FDA has approved a new treatment for “wet” AMD. Known as Vabysmo™, it can extend time between treatments for up to four months.
Early research suggests that modifying cross-talk between the eye’s immune and vascular systems may be a new way to treat AMD.
Extracellular vesicles isolated from the blood of people with Down syndrome-related Alzheimer’s disease have been shown to seed toxic tau species in the brains of normal mice, shedding light on the uptake and transmission of toxic tau.
